West Pharmaceutical beats Q3 net sales estimates; lifts FY revenue, EPS outlook

West Pharmaceutical Services

23/10/2025 11:14

Overview

West Pharmaceutical Services Q3 net sales up 7.7%, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company raises full-year 2025 revenue and EPS guidance, citing ongoing momentum

Outlook

West Pharmaceutical raises full-year 2025 revenue guidance to $3.060 bln-$3.070 bln

Company increases full-year 2025 adjusted EPS guidance to $7.06-$7.11

West Pharmaceutical introduces Q4 2025 revenue guidance of $790 mln-$800 mln

Company sets Q4 2025 adjusted EPS guidance at $1.81-$1.86

Result Drivers

HVP COMPONENTS GROWTH - Double-digit growth in HVP Components driven by GLP-1 products and increased HVP conversion

CONTRACT MANUFACTURING - Growth in Contract Manufacturing driven by self-injection devices for obesity and diabetes

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 NET SALES
Beat
$804.60 mln
$787.92 mln (11 Analysts)
Q3 ADJUSTED EPS
Beat
$1.96
$1.68 (12 Analysts)
Q3 EPS
$1.92


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for West Pharmaceutical Services Inc is $311.00, about 10.2% above its October 21 closing price of $279.39

The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release: ID:nPn8GkbP3a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)